Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-10

AUTHORS

J. Braess, W. Kern, M. Unterhalt, C. C. Kaufmann, B. Ramsauer, M. Schüssler, A. Kaeser-Fröhlich, W. Hiddemann, E. Schleyer

ABSTRACT

Cytarabine ocfosfate (YNK01) is a novel orally applicable prodrug of cytosine arabinoside. Recent pharmacokinetic studies have revealed a prolonged release of the cytotoxic agent cytosine arabinoside (araC) from hepatocytes into the systemic circulation, resulting in a half-life of approximately 24 h for araC. The specific pharmacokinetic characteristics of cytarabine ocfosfate lead to a prolonged exposure of leukemic cells to this antineoplasstic agent during the 14-day cycle. the oral applicability during outpatient treatment and the sustained antineoplastic activity of araC against slowly proliferating leukemic B-cells suggest that cytarabine ocfosfate might be a useful drug in the treatment of chronic lymphocytic leukemia. Four years after diagnosis of B-CLL, a 50-year-old patient was started on cytarabine ocfosfate. Sequentially, the patient's disease had proved refractory to treatment with chlorambucil/prednisone (31 months), fludarabine (5 months), and prednimustine/mitoxantrone (3 months). These established regimens were discontinued because of increasing lymphocytosis, significant thrombocytopenia, and progressive B-symptoms. Following three cycles of cytarabine ocfosfate B-symptoms resolved, lymphadenopathy disappeared, and thrombocytopenia was significantly reduced. The patient has been free of these symptoms on a dosage of 1500 mg cytarabine ocfosfate/day (cycle of 14 days with intervals of 14-21 days) for 24 months and remains in an ongoing partial remission. More... »

PAGES

201-204

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002770050229

DOI

http://dx.doi.org/10.1007/s002770050229

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008948024

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/8890711


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arabinonucleotides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytidine Monophosphate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Lymphocytic, Chronic, B-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prodrugs", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of G\u00f6ttingen", 
          "id": "https://www.grid.ac/institutes/grid.7450.6", 
          "name": [
            "Department of Internal Medicine, Division of Hematology and Oncology, University of G\u00f6ttingen, Robert-Koch-Strasse 40, D-37075 G\u00f6ttingen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Braess", 
        "givenName": "J.", 
        "id": "sg:person.0730272316.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730272316.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of G\u00f6ttingen", 
          "id": "https://www.grid.ac/institutes/grid.7450.6", 
          "name": [
            "Department of Internal Medicine, Division of Hematology and Oncology, University of G\u00f6ttingen, Robert-Koch-Strasse 40, D-37075 G\u00f6ttingen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kern", 
        "givenName": "W.", 
        "id": "sg:person.016053332122.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016053332122.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of G\u00f6ttingen", 
          "id": "https://www.grid.ac/institutes/grid.7450.6", 
          "name": [
            "Department of Internal Medicine, Division of Hematology and Oncology, University of G\u00f6ttingen, Robert-Koch-Strasse 40, D-37075 G\u00f6ttingen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Unterhalt", 
        "givenName": "M.", 
        "id": "sg:person.01361062121.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361062121.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of G\u00f6ttingen", 
          "id": "https://www.grid.ac/institutes/grid.7450.6", 
          "name": [
            "Department of Internal Medicine, Division of Hematology and Oncology, University of G\u00f6ttingen, Robert-Koch-Strasse 40, D-37075 G\u00f6ttingen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaufmann", 
        "givenName": "C. C.", 
        "id": "sg:person.0726021440.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726021440.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of G\u00f6ttingen", 
          "id": "https://www.grid.ac/institutes/grid.7450.6", 
          "name": [
            "Department of Internal Medicine, Division of Hematology and Oncology, University of G\u00f6ttingen, Robert-Koch-Strasse 40, D-37075 G\u00f6ttingen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ramsauer", 
        "givenName": "B.", 
        "id": "sg:person.01335177140.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335177140.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evonik (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420017.0", 
          "name": [
            "ASTA Medica, Frankfurt/M, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sch\u00fcssler", 
        "givenName": "M.", 
        "id": "sg:person.01250747630.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250747630.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evonik (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420017.0", 
          "name": [
            "ASTA Medica, Frankfurt/M, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaeser-Fr\u00f6hlich", 
        "givenName": "A.", 
        "id": "sg:person.01215301435.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215301435.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of G\u00f6ttingen", 
          "id": "https://www.grid.ac/institutes/grid.7450.6", 
          "name": [
            "Department of Internal Medicine, Division of Hematology and Oncology, University of G\u00f6ttingen, Robert-Koch-Strasse 40, D-37075 G\u00f6ttingen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hiddemann", 
        "givenName": "W.", 
        "id": "sg:person.01116433725.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116433725.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of G\u00f6ttingen", 
          "id": "https://www.grid.ac/institutes/grid.7450.6", 
          "name": [
            "Department of Internal Medicine, Division of Hematology and Oncology, University of G\u00f6ttingen, Robert-Koch-Strasse 40, D-37075 G\u00f6ttingen, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schleyer", 
        "givenName": "E.", 
        "id": "sg:person.01017713021.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017713021.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00686108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009234973", 
          "https://doi.org/10.1007/bf00686108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00686108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009234973", 
          "https://doi.org/10.1007/bf00686108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036959406"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-120-9-199405010-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073698672"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1996-10", 
    "datePublishedReg": "1996-10-01", 
    "description": "Cytarabine ocfosfate (YNK01) is a novel orally applicable prodrug of cytosine arabinoside. Recent pharmacokinetic studies have revealed a prolonged release of the cytotoxic agent cytosine arabinoside (araC) from hepatocytes into the systemic circulation, resulting in a half-life of approximately 24 h for araC. The specific pharmacokinetic characteristics of cytarabine ocfosfate lead to a prolonged exposure of leukemic cells to this antineoplasstic agent during the 14-day cycle. the oral applicability during outpatient treatment and the sustained antineoplastic activity of araC against slowly proliferating leukemic B-cells suggest that cytarabine ocfosfate might be a useful drug in the treatment of chronic lymphocytic leukemia. Four years after diagnosis of B-CLL, a 50-year-old patient was started on cytarabine ocfosfate. Sequentially, the patient's disease had proved refractory to treatment with chlorambucil/prednisone (31 months), fludarabine (5 months), and prednimustine/mitoxantrone (3 months). These established regimens were discontinued because of increasing lymphocytosis, significant thrombocytopenia, and progressive B-symptoms. Following three cycles of cytarabine ocfosfate B-symptoms resolved, lymphadenopathy disappeared, and thrombocytopenia was significantly reduced. The patient has been free of these symptoms on a dosage of 1500 mg cytarabine ocfosfate/day (cycle of 14 days with intervals of 14-21 days) for 24 months and remains in an ongoing partial remission.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s002770050229", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1018247", 
        "issn": [
          "1269-3286", 
          "1279-8509"
        ], 
        "name": "Annals of Hematology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "73"
      }
    ], 
    "name": "Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone", 
    "pagination": "201-204", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2aa0e57d5a44ab17d9100685ba153f2c9582fc3a34ffa3cb55fee3d3e54c79ac"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "8890711"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9107334"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002770050229"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008948024"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002770050229", 
      "https://app.dimensions.ai/details/publication/pub.1008948024"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000480.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s002770050229"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002770050229'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002770050229'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002770050229'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002770050229'


 

This table displays all metadata directly associated to this object as RDF triples.

174 TRIPLES      21 PREDICATES      41 URIs      30 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002770050229 schema:about N2112b424ab1c4874ac7809052f95953f
2 N24673e67592148b0850aab201c22ed6c
3 N415ab2c6c8444accbb28ade2c204bd2c
4 N578355b89c194558ba2e887e7ac7d263
5 N9cfb2d03c1bd433fb3c023a6ea91a21f
6 Na283cb04fa1a4c958f88bbc1dac0dce1
7 Nabfc35afcb744a3cb2c32c61a52ed0c1
8 Nd0150da89d2e4c84b9f2adafd68a99ce
9 Nde45c03b97c147d1adff542c3e356e87
10 anzsrc-for:11
11 anzsrc-for:1102
12 schema:author N5aedde5b34e9414785994c8ecab6c38e
13 schema:citation sg:pub.10.1007/bf00686108
14 https://doi.org/10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v
15 https://doi.org/10.7326/0003-4819-120-9-199405010-00010
16 schema:datePublished 1996-10
17 schema:datePublishedReg 1996-10-01
18 schema:description Cytarabine ocfosfate (YNK01) is a novel orally applicable prodrug of cytosine arabinoside. Recent pharmacokinetic studies have revealed a prolonged release of the cytotoxic agent cytosine arabinoside (araC) from hepatocytes into the systemic circulation, resulting in a half-life of approximately 24 h for araC. The specific pharmacokinetic characteristics of cytarabine ocfosfate lead to a prolonged exposure of leukemic cells to this antineoplasstic agent during the 14-day cycle. the oral applicability during outpatient treatment and the sustained antineoplastic activity of araC against slowly proliferating leukemic B-cells suggest that cytarabine ocfosfate might be a useful drug in the treatment of chronic lymphocytic leukemia. Four years after diagnosis of B-CLL, a 50-year-old patient was started on cytarabine ocfosfate. Sequentially, the patient's disease had proved refractory to treatment with chlorambucil/prednisone (31 months), fludarabine (5 months), and prednimustine/mitoxantrone (3 months). These established regimens were discontinued because of increasing lymphocytosis, significant thrombocytopenia, and progressive B-symptoms. Following three cycles of cytarabine ocfosfate B-symptoms resolved, lymphadenopathy disappeared, and thrombocytopenia was significantly reduced. The patient has been free of these symptoms on a dosage of 1500 mg cytarabine ocfosfate/day (cycle of 14 days with intervals of 14-21 days) for 24 months and remains in an ongoing partial remission.
19 schema:genre research_article
20 schema:inLanguage en
21 schema:isAccessibleForFree false
22 schema:isPartOf N711a1fe5e54d4762b10e4421b983198c
23 Nf07ab77d3a70412e91cf284756d3ec77
24 sg:journal.1018247
25 schema:name Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone
26 schema:pagination 201-204
27 schema:productId N54c9b2435d844f1889bea5a298f21d26
28 N6f21c9e469ff4afc84f5d3ec35e7d8ab
29 N72a02db2955d4b9595a66cda387da87e
30 N769773ec25e64d5e8c68a621e167ca3a
31 Nc2b45826233d4d6ba4ffb649a4e5a173
32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008948024
33 https://doi.org/10.1007/s002770050229
34 schema:sdDatePublished 2019-04-10T21:29
35 schema:sdLicense https://scigraph.springernature.com/explorer/license/
36 schema:sdPublisher N638315e06989477f90dfd760253f2243
37 schema:url http://link.springer.com/10.1007/s002770050229
38 sgo:license sg:explorer/license/
39 sgo:sdDataset articles
40 rdf:type schema:ScholarlyArticle
41 N1c133e50313c424f9d290fd0faa9813d rdf:first sg:person.01361062121.82
42 rdf:rest Nc8cd3aa67c83481f94944d10b414f325
43 N2112b424ab1c4874ac7809052f95953f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
44 schema:name Antimetabolites, Antineoplastic
45 rdf:type schema:DefinedTerm
46 N24673e67592148b0850aab201c22ed6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
47 schema:name Humans
48 rdf:type schema:DefinedTerm
49 N3a37ae7e298d4e929b3defc04b158eaf rdf:first sg:person.016053332122.16
50 rdf:rest N1c133e50313c424f9d290fd0faa9813d
51 N415ab2c6c8444accbb28ade2c204bd2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
52 schema:name Leukemia, Lymphocytic, Chronic, B-Cell
53 rdf:type schema:DefinedTerm
54 N417f9b5c9c2c41aaad63683465c6580f rdf:first sg:person.01335177140.83
55 rdf:rest Nd39ee6de8b194110ac6862acdbeb3767
56 N54c9b2435d844f1889bea5a298f21d26 schema:name readcube_id
57 schema:value 2aa0e57d5a44ab17d9100685ba153f2c9582fc3a34ffa3cb55fee3d3e54c79ac
58 rdf:type schema:PropertyValue
59 N578355b89c194558ba2e887e7ac7d263 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Prodrugs
61 rdf:type schema:DefinedTerm
62 N5aedde5b34e9414785994c8ecab6c38e rdf:first sg:person.0730272316.08
63 rdf:rest N3a37ae7e298d4e929b3defc04b158eaf
64 N638315e06989477f90dfd760253f2243 schema:name Springer Nature - SN SciGraph project
65 rdf:type schema:Organization
66 N6f21c9e469ff4afc84f5d3ec35e7d8ab schema:name doi
67 schema:value 10.1007/s002770050229
68 rdf:type schema:PropertyValue
69 N711a1fe5e54d4762b10e4421b983198c schema:volumeNumber 73
70 rdf:type schema:PublicationVolume
71 N72a02db2955d4b9595a66cda387da87e schema:name dimensions_id
72 schema:value pub.1008948024
73 rdf:type schema:PropertyValue
74 N769773ec25e64d5e8c68a621e167ca3a schema:name nlm_unique_id
75 schema:value 9107334
76 rdf:type schema:PropertyValue
77 N9cfb2d03c1bd433fb3c023a6ea91a21f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Middle Aged
79 rdf:type schema:DefinedTerm
80 N9f42b1d75b664d9bbf58696d44219912 rdf:first sg:person.01215301435.50
81 rdf:rest Naf072f1da5fb468da4969e1b2ace1599
82 Na283cb04fa1a4c958f88bbc1dac0dce1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Administration, Oral
84 rdf:type schema:DefinedTerm
85 Nabfc35afcb744a3cb2c32c61a52ed0c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Arabinonucleotides
87 rdf:type schema:DefinedTerm
88 Naf072f1da5fb468da4969e1b2ace1599 rdf:first sg:person.01116433725.53
89 rdf:rest Ne68a610d60374b4a813ce7ea37cca053
90 Nc2b45826233d4d6ba4ffb649a4e5a173 schema:name pubmed_id
91 schema:value 8890711
92 rdf:type schema:PropertyValue
93 Nc8cd3aa67c83481f94944d10b414f325 rdf:first sg:person.0726021440.52
94 rdf:rest N417f9b5c9c2c41aaad63683465c6580f
95 Nd0150da89d2e4c84b9f2adafd68a99ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Male
97 rdf:type schema:DefinedTerm
98 Nd39ee6de8b194110ac6862acdbeb3767 rdf:first sg:person.01250747630.61
99 rdf:rest N9f42b1d75b664d9bbf58696d44219912
100 Nde45c03b97c147d1adff542c3e356e87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Cytidine Monophosphate
102 rdf:type schema:DefinedTerm
103 Ne68a610d60374b4a813ce7ea37cca053 rdf:first sg:person.01017713021.62
104 rdf:rest rdf:nil
105 Nf07ab77d3a70412e91cf284756d3ec77 schema:issueNumber 4
106 rdf:type schema:PublicationIssue
107 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
108 schema:name Medical and Health Sciences
109 rdf:type schema:DefinedTerm
110 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
111 schema:name Cardiorespiratory Medicine and Haematology
112 rdf:type schema:DefinedTerm
113 sg:journal.1018247 schema:issn 1269-3286
114 1279-8509
115 schema:name Annals of Hematology
116 rdf:type schema:Periodical
117 sg:person.01017713021.62 schema:affiliation https://www.grid.ac/institutes/grid.7450.6
118 schema:familyName Schleyer
119 schema:givenName E.
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017713021.62
121 rdf:type schema:Person
122 sg:person.01116433725.53 schema:affiliation https://www.grid.ac/institutes/grid.7450.6
123 schema:familyName Hiddemann
124 schema:givenName W.
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116433725.53
126 rdf:type schema:Person
127 sg:person.01215301435.50 schema:affiliation https://www.grid.ac/institutes/grid.420017.0
128 schema:familyName Kaeser-Fröhlich
129 schema:givenName A.
130 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215301435.50
131 rdf:type schema:Person
132 sg:person.01250747630.61 schema:affiliation https://www.grid.ac/institutes/grid.420017.0
133 schema:familyName Schüssler
134 schema:givenName M.
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250747630.61
136 rdf:type schema:Person
137 sg:person.01335177140.83 schema:affiliation https://www.grid.ac/institutes/grid.7450.6
138 schema:familyName Ramsauer
139 schema:givenName B.
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335177140.83
141 rdf:type schema:Person
142 sg:person.01361062121.82 schema:affiliation https://www.grid.ac/institutes/grid.7450.6
143 schema:familyName Unterhalt
144 schema:givenName M.
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361062121.82
146 rdf:type schema:Person
147 sg:person.016053332122.16 schema:affiliation https://www.grid.ac/institutes/grid.7450.6
148 schema:familyName Kern
149 schema:givenName W.
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016053332122.16
151 rdf:type schema:Person
152 sg:person.0726021440.52 schema:affiliation https://www.grid.ac/institutes/grid.7450.6
153 schema:familyName Kaufmann
154 schema:givenName C. C.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726021440.52
156 rdf:type schema:Person
157 sg:person.0730272316.08 schema:affiliation https://www.grid.ac/institutes/grid.7450.6
158 schema:familyName Braess
159 schema:givenName J.
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730272316.08
161 rdf:type schema:Person
162 sg:pub.10.1007/bf00686108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009234973
163 https://doi.org/10.1007/bf00686108
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v schema:sameAs https://app.dimensions.ai/details/publication/pub.1036959406
166 rdf:type schema:CreativeWork
167 https://doi.org/10.7326/0003-4819-120-9-199405010-00010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073698672
168 rdf:type schema:CreativeWork
169 https://www.grid.ac/institutes/grid.420017.0 schema:alternateName Evonik (Germany)
170 schema:name ASTA Medica, Frankfurt/M, Germany, DE
171 rdf:type schema:Organization
172 https://www.grid.ac/institutes/grid.7450.6 schema:alternateName University of Göttingen
173 schema:name Department of Internal Medicine, Division of Hematology and Oncology, University of Göttingen, Robert-Koch-Strasse 40, D-37075 Göttingen, Germany, DE
174 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...